

## Buy

Recommendation unchanged

**Share price: EUR 85.94**

closing price as of 20/04/2017

**Target price: EUR 100.00**

Target Price unchanged

**Upside/Downside Potential 16.4%**

Reuters/Bloomberg HYQn.DE/HYQ GR

**Market capitalisation (EURm) 532**

Current N° of shares (m) 6

**Free float 63%**

Daily avg. no. trad. sh. 12 mth 20

Daily avg. trad. vol. 12 mth (m) 664.79

Price high/low 12 months 60.58 / 97.00


Abs Perfs 1/3/12 mths (%) -2.89/-0.77/36.24

### Key financials (EUR)

	12/16p	12/17e	12/18e
Sales (m)	157	174	189
EBITDA (m)	30	33	37
EBITDA margin	19.0%	19.1%	19.4%
EBIT (m)	23	28	31
EBIT margin	14.8%	15.9%	16.2%
Net Profit (adj.)(m)	18	21	24
ROCE	37.8%	46.7%	54.4%
Net debt/(cash) (m)	(18)	(40)	(65)
Net Debt/Equity	-0.3	-0.4	-0.6
Debt/EBITDA	-0.6	-1.2	-1.8
Int. cover(EBITDA/Fin. int)	19.9	15.1	21.0
EV/Sales	3.0	2.8	2.5
EV/EBITDA	15.6	14.8	12.7
EV/EBITDA (adj.)	15.6	14.8	12.7
EV/EBIT	20.0	17.8	15.2
P/E (adj.)	25.9	24.7	21.7
P/BV	6.8	5.8	4.6
OpFCF yield	3.7%	4.0%	4.7%
Dividend yield	0.0%	0.0%	0.0%
EPS (adj.)	3.00	3.49	3.96
BVPS	11.38	14.78	18.64
DPS	0.00	0.00	0.00

### Shareholders

Slabke 37%;



### Analyst(s)

Philipp Hässler, CFA  
 philipp.haessler@equinet-ag.de  
 +49 69 58997 414


## Strong Europe Q1 figures

**The facts:** This morning HYP has reported strong Q1 transaction figures. Europe transaction volume was up by 17% yoy to EUR 12.2.bn. Given the stable market development in January and February we had not expected such a strong performance. Growth was particularly strong at FINMAS (+63% yoy) and at GENOPACE (+52% yoy). Q1 growth rate of 17% yoy was the strongest since Q4 '15.

**Our analysis:** As the mortgage loan market (based upon Bundesbank figures) has grown by only 1% yoy, i.e. assuming that March has shown a similar development (which is probably too optimistic as March 2016 was a particularly strong month) Hypoport seems to have won further market share in Q1 (Europe transaction volumes include consumer loans as well, which contribute however only around 5% to total Europe transaction volumes). Positively, Hypoport has further improved its market position among savings and mutual banks. FINMAS, its joint venture with the savings banking sector, reported an increase of Europe transaction volumes by 63% yoy to EUR 0.5bn and GENOPACE, HYP's joint venture with mutual banking sector, reported an increase by 52% yoy to EUR 0.3bn.

### Development of Europe transaction volumes

(in EUR bn; sources: Hypoport, equinet)



**Conclusion & Action:** The strong Europe Q1 transaction volumes clearly come as a positive surprise. This bodes well for good Q1 results. We reiterate our Buy recommendation with a target price of EUR 100.00.